The Pfizer-BioNTech vaccine for COVID-19 has been shown to reduce the inflammation profile in PF-associated COVID-19 patients by reducing the levels of GIP-10, Gal-3, HIF-1, WBC, and ESR. This evidence concerns the gene LGALS3 and COVID-19.